Overall Survival and Long-Term Safety of Nivolumab (Anti-Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer.

By S. Gettinger, L. Horn, L. Gandhi, D. Spigel, S. Antonia, N. Rizvi, J. Powderly, R. Heist, R. Carvajal, D. Jackman and 19 more. Journal of Clinical Oncology, 2015

1,081 citations recorded by the source corpus.

Subfields: Oncology

View Paper: https://www.semanticscholar.org/paper/3bc9000e01ac7a7ab934145e649e71ca73a03896

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Oncology

1. J. Wolchok
2. M. Postow
3. C. Robert
4. M. Hellmann
5. K. Kerr
6. K. Schindler
7. L. Connell
8. D. Page

Citations in the corpus

• Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2017, background): “Development of vitiligo is predominantly observed in melanoma patients treated with ICPis but not in NSCLC or renal cancer.”
• Nivolumab in Resected and Unresectable Metastatic Melanoma: Characteristics of Immune-Related Adverse Events and Association with Outcomes (2015, background): “PD-1 blockade to enhance antitumor immunity has led to durable clinical responses in patients with advanced melanoma, other solid tumors (29, 30), and Hodgkin lymphoma (31) and appears to have a favorable immune toxicity profile.”
• Immune-related adverse events with immune checkpoint blockade: a comprehensive review. (2016, background): “[70] Gettinger SN, Horn L, Gandhi L, Spigel DR, Antonia SJ, Rizvi NA, et al.”